Sfmg LLC Sells 1,488 Shares of Bristol-Myers Squibb (NYSE:BMY)

Sfmg LLC lowered its stake in Bristol-Myers Squibb (NYSE:BMY) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,192 shares of the biopharmaceutical company’s stock after selling 1,488 shares during the period. Sfmg LLC’s holdings in Bristol-Myers Squibb were worth $1,600,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. True Wealth Design LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $26,000. Coppell Advisory Solutions Corp. purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $31,000. Coppell Advisory Solutions LLC purchased a new position in Bristol-Myers Squibb during the second quarter valued at $28,000. Live Oak Investment Partners purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $33,000. Finally, OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb during the third quarter valued at $25,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.5 %

Bristol-Myers Squibb stock traded down $0.25 during mid-day trading on Wednesday, hitting $48.26. The company’s stock had a trading volume of 11,931,277 shares, compared to its average volume of 10,940,481. The company has a 50 day moving average of $51.27 and a 200-day moving average of $51.62. The stock has a market cap of $97.81 billion, a PE ratio of 12.50, a P/E/G ratio of 1.46 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the prior year, the company earned $1.82 EPS. The business’s revenue was up .6% compared to the same quarter last year. On average, research analysts anticipate that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.97%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.18%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Wells Fargo & Company lowered their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 6th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $61.12.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.